share_log

Is New Journey Health Technology GroupLTD (SZSE:002219) Using Too Much Debt?

Is New Journey Health Technology GroupLTD (SZSE:002219) Using Too Much Debt?

新旅健康科技集團有限公司(SZSE:002219)是否使用過多債務?
Simply Wall St ·  06/26 02:20

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. As with many other companies New Journey Health Technology Group Co.,LTD (SZSE:002219) makes use of debt. But should shareholders be worried about its use of debt?

David Iben曾言:'波動性不是我們關心的風險。我們關心的是避免資本永久損失。' 因此,當你考慮一隻股票的風險時,需要考慮債務,因爲過多的債務可能會使一家公司垮掉。與許多其他公司一樣,深圳市新里程健康科技股份有限公司(深交所股票代碼:002219)也使用債務。但股東們應該擔心其使用的債務嗎?

Why Does Debt Bring Risk?

爲什麼債務會帶來風險?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. Part and parcel of capitalism is the process of 'creative destruction' where failed businesses are mercilessly liquidated by their bankers. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. When we examine debt levels, we first consider both cash and debt levels, together.

債務可以幫助企業,直到企業開始有支付的問題,無論是通過新的資本還是通過自身的自由現金流。資本主義的一個部分是“創造性的毀滅”過程,債權人會殘忍地清算失敗的企業。然而,更常見的情況下,企業要以低價募集新的股權資本,從而永久性地稀釋股東的權益。話雖如此,最常見的情況是企業合理地管理其債務——並使其達到自身的優勢。當我們審查債務水平時,首先要考慮現金和債務水平。

What Is New Journey Health Technology GroupLTD's Debt?

新里程健康科技股份有限公司的債務是多少?

As you can see below, at the end of March 2024, New Journey Health Technology GroupLTD had CN¥1.69b of debt, up from CN¥963.6m a year ago. Click the image for more detail. However, it does have CN¥493.7m in cash offsetting this, leading to net debt of about CN¥1.19b.

正如下圖所示,在2024年3月底,新里程健康科技股份有限公司的債務爲1.69億人民幣,高於一年前的9636萬元人民幣。點擊圖片以了解更多詳細信息。但是,它有4,937萬元人民幣的現金抵消,導致其淨債務約爲11.9億元人民幣。

debt-equity-history-analysis
SZSE:002219 Debt to Equity History June 26th 2024
深交所股票代碼:002219債務權益歷史記錄2024年6月26日

How Strong Is New Journey Health Technology GroupLTD's Balance Sheet?

根據最近的資產負債表,新里程健康科技股份有限公司有301億元人民幣的負債到12個月內到期,以及8952萬元人民幣的負債超過12個月到期。相應的,它有4,937萬元人民幣的現金,以及12.6億元人民幣的應收賬款,這些應收賬款在12個月內到期。因此,其負債總計比其現金和短期應收賬款的組合多215億元人民幣。

According to the last reported balance sheet, New Journey Health Technology GroupLTD had liabilities of CN¥3.01b due within 12 months, and liabilities of CN¥895.2m due beyond 12 months. Offsetting this, it had CN¥493.7m in cash and CN¥1.26b in receivables that were due within 12 months. So its liabilities total CN¥2.15b more than the combination of its cash and short-term receivables.

雖然這聽起來很多,但由於新里程健康科技股份有限公司的市值爲64.1億元人民幣,因此它可以通過募集資本來加強其資產負債表。但很明顯,我們確實需要仔細考慮它是否可以在沒有稀釋股權的情況下管理其債務。

While this might seem like a lot, it is not so bad since New Journey Health Technology GroupLTD has a market capitalization of CN¥6.41b, and so it could probably strengthen its balance sheet by raising capital if it needed to. But it's clear that we should definitely closely examine whether it can manage its debt without dilution.

雖然新里程健康科技股份有限公司的負債至稅前利潤倍數(3.1)表明它負債,但其利息保障倍數非常薄弱,爲1.8,表明它的槓桿率較高。似乎該企業負擔了大量的折舊和攤銷費用,因此也許其債務負擔比一開始看到的更重,因爲稅前利潤(EBITDA)可以說是收益的寬鬆度量。因此,股東可能應該知道,利息支出似乎最近確實對企業產生了重大影響。更糟糕的是,新里程健康科技股份有限公司的稅前收益在過去12個月內下跌了22%。如果利潤繼續沿着那條軌跡發展,償還那筆債務將比說服我們在雨中跑馬拉松更困難。毫無疑問,我們從資產負債表中了解到最多的是有關債務的信息。但是,由於新里程健康科技股份有限公司需要創造盈利來服務其債務,因此您不能單獨查看債務。因此,如果您想了解更多關於其盈利的信息,可能值得查看其長期盈利趨勢的圖表。

In order to size up a company's debt relative to its earnings, we calculate its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and its earnings before interest and tax (EBIT) divided by its interest expense (its interest cover). The advantage of this approach is that we take into account both the absolute quantum of debt (with net debt to EBITDA) and the actual interest expenses associated with that debt (with its interest cover ratio).

爲了衡量公司相對於其收益的債務情況,我們計算其淨負債除以利息、稅項、折舊和攤銷前收益(EBITDA)和其利息支出除以利息前收益(EBIT)的比例(其利息覆蓋率)。這種方法的優點是,我們既考慮了債務的絕對量(淨負債與 EBITDA),又考慮到了與該債務相關的實際利息支出(其利息覆蓋率)。

While New Journey Health Technology GroupLTD's debt to EBITDA ratio (3.1) suggests that it uses some debt, its interest cover is very weak, at 1.8, suggesting high leverage. It seems that the business incurs large depreciation and amortisation charges, so maybe its debt load is heavier than it would first appear, since EBITDA is arguably a generous measure of earnings. So shareholders should probably be aware that interest expenses appear to have really impacted the business lately. Even worse, New Journey Health Technology GroupLTD saw its EBIT tank 22% over the last 12 months. If earnings continue to follow that trajectory, paying off that debt load will be harder than convincing us to run a marathon in the rain. There's no doubt that we learn most about debt from the balance sheet. But you can't view debt in total isolation; since New Journey Health Technology GroupLTD will need earnings to service that debt. So if you're keen to discover more about its earnings, it might be worth checking out this graph of its long term earnings trend.

最後,儘管稅務部門可能喜歡會計利潤,但貸方只接受現金。 因此,我們總是檢查多少EBIT轉化爲自由現金流。 從最近三年來看,新里程健康科技股份有限公司的自由現金流爲其EBIT的42%,比我們預期的要弱。 對於償還債務來說,這並不是很好的情況。

Finally, while the tax-man may adore accounting profits, lenders only accept cold hard cash. So we always check how much of that EBIT is translated into free cash flow. Looking at the most recent three years, New Journey Health Technology GroupLTD recorded free cash flow of 42% of its EBIT, which is weaker than we'd expect. That's not great, when it comes to paying down debt.

表面上看,新里程健康科技股份有限公司的利息保障倍數讓我們對股票持有猶豫不決,它的EBIT增長率也不太令人感興趣,就像一年中最繁忙的夜晚只有一家空無一人的餐廳。但至少,其總負債水平並不算太糟糕。另外,值得注意的是,新里程健康科技股份有限公司處於衛生保健行業,通常被認爲具有相當的防禦性。從資產負債表中觀察並考慮所有這些因素,我們確實認爲債務使得新里程健康科技股份有限公司的股票有點風險。這並不一定是件壞事,但我們通常會對槓桿率小一些的公司感到更加舒適。在分析債務水平時,資產負債表是顯而易見的起點。但是,最終,每個公司都可能存在超出資產負債表之外的風險。例如,新里程健康科技股份有限公司存在3個警告標誌(1個不應忽略),我們認爲您應該知道它們。

Our View

我們的觀點

On the face of it, New Journey Health Technology GroupLTD's interest cover left us tentative about the stock, and its EBIT growth rate was no more enticing than the one empty restaurant on the busiest night of the year. But at least its level of total liabilities is not so bad. It's also worth noting that New Journey Health Technology GroupLTD is in the Healthcare industry, which is often considered to be quite defensive. Looking at the balance sheet and taking into account all these factors, we do believe that debt is making New Journey Health Technology GroupLTD stock a bit risky. That's not necessarily a bad thing, but we'd generally feel more comfortable with less leverage. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately, every company can contain risks that exist outside of the balance sheet. For example New Journey Health Technology GroupLTD has 3 warning signs (and 1 which shouldn't be ignored) we think you should know about.

多年以來,David Iben的話已經傳遍了股市:'波動性不是我們關心的風險。我們關心的是避免資本永久損失。' 因此,當您開始考慮一隻股票的風險時,需要考慮債務,因爲過多的債務可能會讓一家公司面臨沉沒的風險。同許多其他公司一樣,深圳市新里程健康科技股份有限公司(深交所股票代碼:002219)也利用債務。但股東們需要擔心它使用債務嗎?來自Simply Wall St的研究分析表明股票可能會面臨失寵。想了解深入的分析嗎?請查看Simply Wall St的新里程健康科技股份有限公司的分析。

At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free.

總的來說,專注於沒有淨債務的公司往往更好。您可以訪問我們的特別列表,其中包含這些公司(所有這些公司都有盈利增長的記錄)。這是免費的。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論